A Cancer Research UK Phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424, and to identify tolerable and effective AZD0424 combination regimens for the treatment of advanced solid tumours.

Trial Profile

A Cancer Research UK Phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424, and to identify tolerable and effective AZD0424 combination regimens for the treatment of advanced solid tumours.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs AZD 0424 (Primary) ; Antineoplastics
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 25 Jul 2016 Status changed from active, no longer recruiting to discontinued as single agent phase completed, and there is insufficient supportive preclinical data to proceed with combination phase
    • 29 Mar 2016 Status changed from suspended to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 16 Oct 2015 Status changed from recruiting to suspended as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top